Skip to main content

Articles

Page 3 of 13

  1. Organoids are established through in vitro 3D culture, and they can mimic the structure and physiological functions of organs or tissues in vivo. Organoids have attracted much attention in recent years. They c...

    Authors: Zhen Fang, Peijuan Li, Fengying Du, Liang Shang and Leping Li
    Citation: Experimental Hematology & Oncology 2023 12:69
    Content type: Review Published on:

  2. Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Onco...

    Authors: Yuanhong Jiang, Siyu Wu, Rong Li, Jiazheng Yu, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Zhenqun Xu, Shijie Li and Xiaonan Chen
    Citation: Experimental Hematology & Oncology 2023 12:68
    Content type: Correspondence Published on:

  3. Increasing evidence suggests that immunotherapy, especially immune checkpoint inhibitors (ICIs), has the potential to facilitate long-term survival in various cancer besides prostate cancer. Emerging evidence ...

    Authors: Fei Wu, Minglei Wang, Tao Zhong, Changyan Xiao, Xiaozheng Chen, Yiheng Huang, Meng Wu, Jinming Yu and Dawei Chen
    Citation: Experimental Hematology & Oncology 2023 12:67
    Content type: Research Published on:

  4. The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing spora...

    Authors: Tingting Zhang, Weiwei Tian, Shuang Wei, Xinyi Lu, Jing An, Shaolong He, Jie Zhao, Zhilin Gao, Li Li, Ke Lian, Qiang Zhou, Huilai Zhang, Liang Wang, Liping Su, Huicong Kang, Ting Niu…
    Citation: Experimental Hematology & Oncology 2023 12:66
    Content type: Review Published on:

  5. Ferroptosis is a regulated cell death mode triggered by iron-dependent toxic membrane lipid peroxidation. As a novel cell death modality that is morphologically and mechanistically different from other forms o...

    Authors: Xiaogang Zheng, Xiaodong Jin, Fei Ye, Xiongxiong Liu, Boyi Yu, Zheng Li, Ting Zhao, Weiqiang Chen, Xinguo Liu, Cuixia Di and Qiang Li
    Citation: Experimental Hematology & Oncology 2023 12:65
    Content type: Review Published on:

  6. T cell-redirecting bispecific antibodies establish a connection between endogenous T cells and tumor cells, activating T cells function to eliminate tumor cells without ex vivo genetic alteration or manipulati...

    Authors: Manling Chen, Xiaoyu Liu, Nan Peng, Ting Zhang, Junli Mou, Huizhen He, Ying Wang, Yingxi Xu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Runxia Gu, Shaowei Qiu, Min Wang and Jianxiang Wang
    Citation: Experimental Hematology & Oncology 2023 12:64
    Content type: Research Published on:

  7. Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (...

    Authors: Stefano Kim, Véronique Vendrely, Angélique Saint, Thierry André, Pauline Vaflard, Emmanuelle Samalin, Simon Pernot, Oliver Bouché, Mustapha Zubir, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Marion Jacquin, Elodie Klajer…
    Citation: Experimental Hematology & Oncology 2023 12:63
    Content type: Correspondence Published on:

  9. Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying...

    Authors: Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li, Chunxia Su, Shengxiang Ren, Fengying Wu, Caicun Zhou and Guanghui Gao
    Citation: Experimental Hematology & Oncology 2023 12:61
    Content type: Research Published on:

  10. Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the bone marrow microenvironment and associated with aging, clonal hematopoiesis, mye...

    Authors: Charan Thej Reddy Vegivinti, Praneeth Reddy Keesari, Sindhusha Veeraballi, Catarina Maria Pina Martins Maia, Ansh Krishnachandra Mehta, Rohit Reddy Lavu, Rahul Kumar Thakur, Sri Harsha Tella, Riya Patel, Venkata Kiranmayi Kakumani, Yashwitha Sai Pulakurthi, Srinivas Aluri, Ritesh Kumar Aggarwal, Nandini Ramachandra, Rongbao Zhao, Srabani Sahu…
    Citation: Experimental Hematology & Oncology 2023 12:60
    Content type: Review Published on:

  12. Tumor initiation, progression, and response to therapies depend to a great extent on interactions between malignant cells and the tumor microenvironment (TME), which denotes the cancerous/non-cancerous cells, ...

    Authors: Yunru Gu, Yuan Fang, Xi Wu, Tingting Xu, Tong Hu, Yangyue Xu, Pei Ma, Qiang Wang and Yongqian Shu
    Citation: Experimental Hematology & Oncology 2023 12:58
    Content type: Review Published on:

  13. Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), w...

    Authors: Xubo Gong, Yi Zhang, Xin He, Milad Moloudizargari, Teng Yu, Lin Wang, Weiwei Liu, Lan Jin, Huiying Xu, Yang Xu, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2023 12:57
    Content type: Correspondence Published on:

  14. Without the clear immunophenotyping of brain metastases (BrMs), the optimal treatment strategy based on PD-1/PD-L1 inhibitor for patients with non-small-cell lung cancer (NSCLC) and BrMs remains unknown.

    Authors: Haowei Wang, Fangfang Liu, Xiaoxia Chen, Chao Zhao, Xuefei Li, Caicun Zhou, Jie Hu, Qian Chu and Tao Jiang
    Citation: Experimental Hematology & Oncology 2023 12:56
    Content type: Research Published on:

  15. Ropeginterferon alfa-2b represents a new-generation pegylated interferon-based therapy and is administered every 2–4 weeks. It is approved for polycythemia vera (PV) treatment in the United States and Europe w...

    Authors: Jie Jin, Lei Zhang, Albert Qin, Daoxiang Wu, Zonghong Shao, Jie Bai, Suning Chen, Minghui Duan, Hu Zhou, Na Xu, Sujiang Zhang, Xuelan Zuo, Xin Du, Li Wang, Pei Li, Xuhan Zhang…
    Citation: Experimental Hematology & Oncology 2023 12:55
    Content type: Correspondence Published on:

  16. Brain metastasis (BM) is an important cause of mortality for cancer patients. Many patients were diagnosed with brain metastases at their first visit who have not received any treatment while a subset of patie...

    Authors: Jianing Chen, Hainan Yang, Chao Zhao, Tao Lin, Da Liu, Weiping Hong, Changguo Shan, Cheng Zhou, Ling Bao, Caicun Zhou, Linbo Cai, Chunxia Su, Zhaoming Zhou and Lei Wen
    Citation: Experimental Hematology & Oncology 2023 12:54
    Content type: Correspondence Published on:

  17. Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate ob...

    Authors: Shiqi Mao, Shuo Yang, Xinyu Liu, Xingya Li, Qiming Wang, Yiping Zhang, Jianhua Chen, Yan Wang, Guanghui Gao, Fengying Wu, Tao Jiang, Jiao Zhang, Ying Yang, Xiang Lin, Xiaoyu Zhu, Caicun Zhou…
    Citation: Experimental Hematology & Oncology 2023 12:53
    Content type: Research Published on:

  18. Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste ho...

    Authors: Bohan Wang, Yachong Liu, Zhibin Liao, Haofeng Wu, Bixiang Zhang and Lei Zhang
    Citation: Experimental Hematology & Oncology 2023 12:52
    Content type: Review Published on:

  19. Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment option...

    Authors: M Spalato-Ceruso, A Laroche-Clary, R Perret, Y Valverde, V Chaire, Marie-Alix Derieppe, V Velasco, A Bourdon and A Italiano
    Citation: Experimental Hematology & Oncology 2023 12:51
    Content type: Correspondence Published on:

  20. Thrombocytopenia occurs in 60% of patients with myelodysplastic syndromes (MDS), increasing the risk of life-threatening haemorrhage in this population of mainly old patients with comorbidities. However, data ...

    Authors: Pauline Durand, Valérie Pottier, Charles Mesguich, Frédéric Debordeaux, Estibaliz Lazaro, Jean-François Viallard and Etienne Rivière
    Citation: Experimental Hematology & Oncology 2023 12:50
    Content type: Correspondence Published on:

  21. Metastasis is a crucial aspect of disease progression leading to death in patients with prostate cancer (PCa). However, its mechanism remains unclear. We aimed to explore the mechanism of lymph node metastasis...

    Authors: Shiyong Xin, Xiang Liu, Ziyao Li, Xianchao Sun, Rong Wang, Zhenhua Zhang, Xinwei Feng, Liang Jin, Weiyi Li, Chaozhi Tang, Wangli Mei, Qiong Cao, Haojie Wang, Jianguo Zhang, Lijin Feng and Lin Ye
    Citation: Experimental Hematology & Oncology 2023 12:49
    Content type: Research Published on:

    The Correction to this article has been published in Experimental Hematology & Oncology 2024 13:54

  22. Approximately 60–80% of cancer patients treated with abdominopelvic radiotherapy suffer post-radiotherapy toxicities including radiation enteropathy and myelosuppression. Effective preventive and therapeutic s...

    Authors: Yuxi Yi, Weiqing Lu, Lijun Shen, Yang Wu and Zhen Zhang
    Citation: Experimental Hematology & Oncology 2023 12:48
    Content type: Review Published on:

  23. Drug resistance and poor treatment response are major obstacles to the effective treatment of acute myeloid leukemia (AML). A deeper understanding of the mechanisms regulating drug resistance and response gene...

    Authors: Xin Liu, Shuxin Zhong, Kangjie Qiu, Xi Chen, Weiyue Wu, Jiamian Zheng, Yanwen Liu, Haolong Wu, Shiyun Fan, Dingrui Nie, Xianfeng Wang, Zhi Yu, Ziwei Liao, Mengjun Zhong, Yangqiu Li and Chengwu Zeng
    Citation: Experimental Hematology & Oncology 2023 12:47
    Content type: Research Published on:

  24. Clear-cell renal cell carcinomas (ccRCCs) are malignant tumors with high metastatic potential and resistance to treatments occurs almost constantly. Compared to primary tumors, there are still limited genomic ...

    Authors: Thi Oanh Bui, Eurydice Angeli, Morad El Bouchtaoui, Guillaume Gapihan, Van Tu Dao, Justine Paris, Christophe Leboeuf, Michael Soussan, Patrick Villarese, Marianne Ziol, Emmanuel Van Glabeke, Thi Huong Le, Jean-Paul Feugeas, Anne Janin and Guilhem Bousquet
    Citation: Experimental Hematology & Oncology 2023 12:46
    Content type: Correspondence Published on:

  25. Venetoclax (Ven) combined with intensive chemotherapy was proven effective in the management of acute myeloid leukemia (AML). However, the severe and prolonged myelosuppression remains a concern to worry about...

    Authors: Xiaohui Suo, Fang Zheng, Dongmei Wang, Liyun Zhao, Jie Liu, Ling Li, Zhihua Zhang, Congcong Zhang, Yinling Li, Sisi Yang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao, Jiaojie Song, Ling Zhang…
    Citation: Experimental Hematology & Oncology 2023 12:45
    Content type: Research Published on:

  26. BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients. However, the short remission time and high relapse rate of MM patients treat...

    Authors: Wei Li, Binglei Zhang, Weijie Cao, Wenli Zhang, Tiandong Li, Lina Liu, LinPing Xu, Fengcai Gao, Yanmei Wang, Fang Wang, Haizhou Xing, Zhongxing Jiang, Jianxiang Shi, Zhilei Bian and Yongping Song
    Citation: Experimental Hematology & Oncology 2023 12:44
    Content type: Research Published on:

  27. Head and neck squamous cell carcinoma (HNSCC) is highly aggressive with a significant tropism of lymph nodes, which restricts treatment options and negatively impacts patient outcomes. Although progress has be...

    Authors: Min Wang, Min Pan, Yanshi Li, Tao Lu, Zhihai Wang, Chuan Liu and Guohua Hu
    Citation: Experimental Hematology & Oncology 2023 12:43
    Content type: Research Published on:

  28. Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 conse...

    Authors: Olisaemeka D. Ogbue, Tariq Kewan, Waled S. Bahaj, Carmelo Gurnari, Valeria Visconte and Jaroslaw P. Maciejewski
    Citation: Experimental Hematology & Oncology 2023 12:42
    Content type: Correspondence Published on:

  29. Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously unt...

    Authors: Zhijuan Lin, Long Liu, Zhifeng Li and Bing Xu
    Citation: Experimental Hematology & Oncology 2023 12:41
    Content type: Correspondence Published on:

  30. We aim to examine the prognostic value of major pathologic response in metastatic lymph nodes (mLN-MPR) after immunochemotherapy in non-small cell lung cancer (NSCLC), and demonstrate the pathological characte...

    Authors: Hongsheng Deng, Shan Xiong, Ran Zhong, Yongmei Zheng, Hengrui Liang, Bo Cheng, Jianfu Li, Feng Li, Zhuxing Chen, Haixuan Wang, Jianxing He and Wenhua Liang
    Citation: Experimental Hematology & Oncology 2023 12:40
    Content type: Correspondence Published on:

  31. WDR5 is a highly conserved protein that performs multiple scaffolding functions in the context of chromatin. However, efforts to understand the function of WDR5 in normal tissues physiologically are quite limi...

    Authors: Lulu Liu, Yanjia Fang, Xiaodan Ding, Weihua Zhou, Remi Terranova, Yan Zhang and He Wang
    Citation: Experimental Hematology & Oncology 2023 12:39
    Content type: Correspondence Published on:

  32. Sustained activation of hepatocyte growth factor (HGF)/c-MET signaling is a major driver of hepatocellular carcinoma (HCC) progression, but underlying mechanism is unclear. ArfGAP With SH3 Domain, Ankyrin Repe...

    Authors: Xiao-Lu Ma, Yan-Yan Nie, Su-Hong Xie, Hui Zheng, Ying Tong, Yan-Chun Wang, Tian-Qing Yan, Xin Meng, Jia-Zhen Cao, Wei-Guo Tang, Lin Guo and Ren-Quan Lu
    Citation: Experimental Hematology & Oncology 2023 12:38
    Content type: Research Published on:

  33. Surgical intervention is the first-line treatment in well-selected hepatocellular carcinoma (HCC) patients. However, only a few patients are suitable to receive radical surgery. We conducted a systematic revie...

    Authors: Po-Lung Cheng, Ping-Hsiu Wu, We-Yu Kao, Yen-Ting Lai, Jason C. Hsu, Jeng-Fong Chiou, Meng-Huang Wu and Hsin-Lun Lee
    Citation: Experimental Hematology & Oncology 2023 12:37
    Content type: Correspondence Published on:

  34. Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen...

    Authors: Yunju Ma, Haiping Dai, Qingya Cui, Sining Liu, Liqing Kang, Xiaying Lian, Wei Cui, Jia Yin, Lingling Liu, Mengjie Cai, Lei Yu, Depei Wu and Xiaowen Tang
    Citation: Experimental Hematology & Oncology 2023 12:36
    Content type: Correspondence Published on:

  35. Circulating monocytic myeloid-derived suppressive cells (M-MDSCs) are implicated as a poor prognostic factor and cause CAR T-cell failure in diffuse large B-cell lymphoma (DLBCL). Triggering receptors expresse...

    Authors: Hao-Yuan Wang, Fu-Chen Yang, Ching-Fen Yang, Yao-Chung Liu, Po-Shen Ko, Chien-Jung Li, Chun-Kuang Tsai, Yi-Lin Chung and Nien-Jung Chen
    Citation: Experimental Hematology & Oncology 2023 12:35
    Content type: Research Published on:

  36. Tumor development relies on a complex and aberrant tissue environment in which cancer cells receive the necessary nutrients for growth, survive through immune escape, and acquire mesenchymal properties that me...

    Authors: Xian-Miao Li, Zhen-Yu Zhao, Xiao Yu, Qi-Dong Xia, Peng Zhou, Shao-Gang Wang, Huan-Lei Wu and Jia Hu
    Citation: Experimental Hematology & Oncology 2023 12:34
    Content type: Review Published on:

  37. Genetic heterogeneity poses a great challenge to the understanding and management of acute myeloid leukemia (AML). Knowledge of the IKZF1 mutation in AML specifically is extremely limited. In a previous work, we ...

    Authors: Xiang Zhang, Aijie Huang, Lixia Liu, Jiayue Qin, Chengcheng Wang, Min Yang, Yinjun Lou, Lei Wang, Xiong Ni, Xiaoxia Hu, Gusheng Tang, Mengmeng Zhang, Shanbo Cao, Liping Mao, Jiejin Qian, Weilai Xu…
    Citation: Experimental Hematology & Oncology 2023 12:33
    Content type: Correspondence Published on:

  38. Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standa...

    Authors: Raphael E. Steiner, Edwin R. Parra, Francisco Vega, Lei Feng, Jason R. Westin, Sattva S. Neelapu, Paolo Strati, Michael R. Green, Christopher R. Flowers, Luisa M. Solis, Ignacio I. Wistuba, Sairah Ahmed, Ranjit Nair, Fredrick B. Hagemeister, Mansoor Noorani and Mario L. Marques-Piubelli
    Citation: Experimental Hematology & Oncology 2023 12:32
    Content type: Correspondence Published on:

  39. Endoplasmic reticulum stress (ER stress) may destroy endoplasmic reticulum homeostasis (ER homeostasis) and leads to programmable cell death. Unfolded protein response (UPR) originally stimulated by ER stress ...

    Authors: Xiaoting Liang, Jieyu Liu, Xingyuan Liu, Yi Jin, Minna Xu, Zhenyu Han, Ke Wang, Chunting Zhang, Fei Zou and Liang Zhou
    Citation: Experimental Hematology & Oncology 2023 12:31
    Content type: Research Published on:

  41. Melanoma is the deadliest form of skin cancer showing rising incidence over the past years. New insights into the mechanisms of melanoma progression contributed to the development of novel treatment options, s...

    Authors: Tamara Steinfass, Juliane Poelchen, Qian Sun, Giovanni Mastrogiulio, Daniel Novak, Marlene Vierthaler, Sandra Pardo, Aniello Federico, Laura Hüser, Thomas Hielscher, Rafael Carretero, Rienk Offringa, Peter Altevogt, Viktor Umansky and Jochen Utikal
    Citation: Experimental Hematology & Oncology 2023 12:29
    Content type: Correspondence Published on:

  42. Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitot...

    Authors: Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Shiyu Xiao, Weilong Zhang, Mingxia Zhu, Yanfang Wang, Xiaoyan Ke and Hongmei Jing
    Citation: Experimental Hematology & Oncology 2023 12:28
    Content type: Research Published on:

  43. As significant posttranslational modifications, ubiquitination and deubiquitination, whose balance is modulated by ubiquitin-conjugating enzymes and deubiquitinating enzymes (DUBs), can regulate many biologica...

    Authors: Xiaoya Ren, Menglong Jiang, Peng Ding, Xiaoyan Zhang, Xin Zhou, Jian Shen, Dong Liu, Xiaolong Yan and Zhiqiang Ma
    Citation: Experimental Hematology & Oncology 2023 12:27
    Content type: Review Published on:

  44. The persistence of tumor load in multiple myeloma (MM) lead to relapse in patients achieving complete remission (CR). Appropriate and effective methods of myeloma tumor load monitoring are important for guidin...

    Authors: Zhao-Yun Liu, Nan-Hao Meng, Pan-Pan Cao, Feng-Ping Peng, Jing-Yi Luo, Hao Wang, Feng-Juan Jiang, Jin Lu and Rong Fu
    Citation: Experimental Hematology & Oncology 2023 12:26
    Content type: Correspondence Published on:

  45. Normal karyotype acute myeloid leukemia (NK-AML) is a heterogeneous hematological malignancy that contains a minor population of self-renewing leukemia stem cells (LSCs), which complicate efforts to achieve lo...

    Authors: Wenqi Wu, Zeyan Shi, Zhongyuan Tang, Huiqun Li, Xiaoke Huang, Xiaolin Liang, Jing Li, Yibin Yao, Weihua Zhao, Meiqing Wu, Jun Luo and Zhenfang Liu
    Citation: Experimental Hematology & Oncology 2023 12:25
    Content type: Research Published on:

  46. Hyperproliferative diseases such as Chronic Lymphocytic Leukemia (CLL) and Systemic Lupus Erythematosus (SLE) are potentially related to some disturbance in the apoptosis pathway, specifically in B-1a cells (CD5+

    Authors: Olívia F Souza, Vivian C de Oliveira, Gabriel J. F. Rodrigues, Lucas V. S. Costa, Fernanda Corado and Ana F. Popi
    Citation: Experimental Hematology & Oncology 2023 12:24
    Content type: Correspondence Published on:

  47. More effective targeted therapy and new combination regimens are needed for Acute myeloid leukemia (AML), owing to the unsatisfactory long-term prognosis of the disease. Here, we investigated the synergistic e...

    Authors: Siyu Gu, Yue Hou, Katarina Dovat, Sinisa Dovat, Chunhua Song and Zheng Ge
    Citation: Experimental Hematology & Oncology 2023 12:23
    Content type: Research Published on:

  48. Lung adenocarcinoma (LUAD) is a major cause of cancer-related death worldwide, and the roles of complement-related genes in it have not been thoroughly investigated yet. In the study, we aimed to systemically ...

    Authors: Lin Zhang, Yannan Yang, Weihao Lin, Fei Shao, Yibo Gao and Jie He
    Citation: Experimental Hematology & Oncology 2023 12:22
    Content type: Correspondence Published on:

  50. Leukemogenic SHP2 mutations occur in 35% of patients with juvenile myelomonocytic leukemia (JMML), a rare but fatal hematopoietic malignancy without representative cell models, which are urgently needed to inv...

    Authors: Yuming Zhao, Chunxiao He, Dengyang Zhang, Yao Guo, Zhiyong Peng, Liuting Yu, Na Li, Chun Chen, Zhizhuang Joe Zhao and Yun Chen
    Citation: Experimental Hematology & Oncology 2023 12:20
    Content type: Correspondence Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 9.4
    5-year Journal Impact Factor: 8.3
    Source Normalized Impact per Paper (SNIP): 1.583
    SCImago Journal Rank (SJR): 2.384

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 100

    Usage 2023
    Downloads: 696,150
    Altmetric mentions: 375

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us